What Is Moroidin? Definition and What Research Reports

Definition

Moroidin is a bicyclic octapeptide — a small, ring-shaped peptide of eight amino acid residues held in a rigid two-ring shape by unusual carbon–carbon and carbon–nitrogen cross-links between tryptophan, leucine and histidine side chains. It occurs naturally in plants, having been first characterised from the stinging tree Dendrocnide moroides (from which it takes its name) and subsequently isolated from the seeds of Celosia argentea and the related ornamental species Celosia cristata (cockscomb). In the peptide literature, moroidin is used as a reference example of a ribosomally synthesised and post-translationally modified peptide (RiPP) of plant origin, and as a natural-product scaffold in cell-based cancer pharmacology experiments. It is a laboratory research compound, not an approved drug, not a dietary ingredient, and not a clinical therapy.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes human use, and no human dosing information exists in the cited literature.

What Class of Molecule Is It?

Moroidin belongs to the cyclopeptide alkaloid / bicyclic peptide family. Several structural features distinguish it from ordinary linear peptides:

• Bicyclic architecture. Two fused macrocycles, rather than a single head-to-tail ring, give the molecule an unusually constrained three-dimensional shape.
• Side-chain cross-links. The rings are closed through side-chain-to-side-chain bonds involving tryptophan, leucine and histidine residues, not through the standard peptide backbone alone.
• Plant origin. Unlike many bicyclic peptides made by bacteria or fungi, moroidin is produced by flowering plants.
• Ribosomal biosynthesis. A 2022 study in the Journal of the American Chemical Society used a gene-guided discovery approach to establish that moroidin peptides are made ribosomally from precursor genes and then modified enzymatically, placing them in the RiPP superfamily (PMID 35438481).

How the term is used in peptide research

"Moroidin" appears in three overlapping contexts in the scientific literature. First, as a natural product: papers describing its isolation, structure elucidation and distribution across plant species. Second, as a biosynthetic case study: researchers interested in how plants assemble complex cross-linked peptides use moroidin and its congeners (sometimes called moroidin-type or celogentin-type peptides) as model substrates. Third, as a tool compound in cell biology: because of reported effects on the cytoskeleton, moroidin has been applied to cultured cell lines in mechanistic experiments. It does not appear in the clinical trial literature, and the cited papers describe no human administration.

What the Published Literature Reports

The evidence base for moroidin is small, laboratory-based and entirely preclinical. The following summarises what the cited papers stated.

Antimitotic and tubulin-related activity

An early report in Bioorganic & Medicinal Chemistry Letters characterised moroidin isolated from the seeds of Celosia argentea and described it as an antimitotic bicyclic peptide that inhibited tubulin polymerisation, the process by which cells assemble the microtubule spindle required for division (PMID 10743950). This antimitotic framing is the reason moroidin is frequently grouped with other natural-product microtubule-interacting peptides in review articles, and it is the mechanism most often referenced in later work.

Apoptosis in a lung cancer cell line

A 2022 paper in the Journal of Natural Products reported moroidin obtained from the seeds of Celosia cristata and described induction of apoptosis — programmed cell death — in A549 human lung cancer cells in culture (PMID 35951980). The study was conducted in cells, not animals or people, and the researchers reported cellular endpoints rather than any clinical outcome.

Glioblastoma vasculogenic mimicry

A 2024 study in the Journal of Biomedical Research reported that moroidin inhibited vasculogenic mimicry — a process in which tumour cells themselves form channel-like structures resembling blood vessels — in glioblastoma cells, and the authors linked this to regulation of β-catenin activation and epithelial–mesenchymal transition (EMT) pathways (PMID 38807414). This was the most mechanistically detailed of the cited reports, but it remained a cell-model investigation.

Biosynthetic access

Because moroidin is present in plant tissue at low abundance and is difficult to synthesise chemically, supply has historically limited research. The gene-guided discovery work described a ribosomal route to moroidin peptides and expanded the known family of related compounds (PMID 35438481). Work of this kind matters mainly because it offers a biological production route for structure–activity studies.

Summary Table of Cited Findings

Safety and Adverse Events: What Studies Report

The cited literature consists of biochemical assays, cell-culture experiments and biosynthetic chemistry. None of the four papers reported human administration, animal toxicology endpoints or adverse event data, so there is no safety profile for moroidin in people to summarise. The absence of reported adverse events in cell-based work should not be read as evidence of safety; it reflects that the question was never asked in these studies. Readers evaluating any compound of this kind should note that microtubule-targeting agents as a class are studied precisely because they interfere with cell division, a property that is not selective to tumour cells by default.

Common Points of Confusion

• Moroidin is not a "performance" or "wellness" peptide. Despite appearing in peptide glossaries, it has no reported use outside cancer-biology and natural-product research.
• The name refers to a plant, not a mechanism. "Moroidin" derives from Dendrocnide moroides; it does not describe the molecule's activity.
• Moroidin is distinct from celogentins. Celogentins are structurally related bicyclic peptides from the same Celosia genus and are often discussed alongside moroidin as members of one family.
• No approved product contains moroidin. It has no marketing authorisation in any jurisdiction and exists in the literature as a research chemical.

Where Research Stands

Across more than two decades of intermittent publication, moroidin has remained a preclinical natural product. The earliest cited work established antimitotic behaviour tied to tubulin (PMID 10743950), while more recent cell studies reported apoptosis in A549 lung cancer cells (PMID 35951980) and effects on glioblastoma vasculogenic mimicry (PMID 38807414). Biosynthetic work has made the compound class more accessible for study (PMID 35438481). There are no randomised trials, no human pharmacokinetic data and no established dosing information of any kind in the cited record. As a glossary entry, the honest description is: a structurally unusual plant bicyclic peptide with early laboratory signals and no clinical evidence base.

References

• Cyclopeptide moroidin inhibits vasculogenic mimicry formed by glioblastoma cells via regulating β-catenin activation and EMT pathways (Journal of Biomedical Research, 2024)
• Moroidin, a Cyclopeptide from the Seeds of Celosia cristata That Induces Apoptosis in A549 Human Lung Cancer Cells (Journal of Natural Products, 2022)
• Gene-Guided Discovery and Ribosomal Biosynthesis of Moroidin Peptides (Journal of the American Chemical Society, 2022)
• Antimitotic activity of moroidin, a bicyclic peptide from the seeds of Celosia argentea (Bioorganic & Medicinal Chemistry Letters, 2000)